Markets:

Overview

News

Currencies

International

Treasuries

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (NY:CANF)

0.3433 +0.0073 (+2.17%)

Streaming Delayed Price Updated: 3:54 PM EST, Nov 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd Sponsored ADR (Israel)

< Previous 1 2 3 4 5 6 7 Next >

Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer

December 28, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Multiple Shots On Goal: Can-Fite’s Late-Stage Clinical Pipeline Hits Positive Results

December 27, 2022

By Ernest Dela Aglanu, Benzinga

Via News Direct

Multiple Shots On Goal: Can-Fite’s Late-Stage Clinical Pipeline Hits Positive Results

December 27, 2022

Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer.

Via TheNewswire.com

Multiple Shots On Goal: Can-Fite's Late-Stage Clinical Pipeline Hits Positive Results ↗

December 13, 2022

Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer.

Via Benzinga

Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis

December 08, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update

November 25, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Meet This BioPharma Company With Several Exciting Drugs In Advanced Clinical Trials ↗

November 09, 2022

Sign up for this week’s All Access giveaway here! Pnina Fishman, Ph.D., CEO of Can-Fite BioPharma (NYSE: CANF), was a guest on Benzinga’s All Access on Nov 4, 2022.

Via Benzinga

Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston

November 02, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers

October 31, 2022

The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.

Via TheNewswire.com

This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers ↗

October 27, 2022

The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.

Via Benzinga

Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®

October 25, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference

October 13, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite BioPharma Ltd. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

September 23, 2022

Via ACCESSWIRE

Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update

August 25, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

September 12, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

August 23, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress

August 22, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix

August 17, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Smoking Pot Makes You 55% Less Likely To Develop This Deadly Cancer ↗

August 03, 2022

Marijuana users have 55% fewer chances of developing, one of the most common malignancies worldwide - hepatocellular carcinoma (HCC), according to a study

Via Benzinga

Industry Analysts Seemingly Sing Praises For This Stock After Phase III Trial Results ↗

July 14, 2022

Psoriasis is a common chronic disease mediated by the immune system. It’s characterized by red, scaly patches that form on the skin. Psoriasis affects more than 3% of the U.S. adult population — over...

Via Benzinga

Boeing, PriceSmart And 80 Biggest Movers From Yesterday ↗

July 13, 2022

Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.

Via Benzinga

Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session ↗

July 12, 2022

Gainers

Via Benzinga

The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death ↗

July 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Alibaba, Zoom Video And 76 Biggest Movers From Yesterday ↗

July 12, 2022

Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media.

Via Benzinga

Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

July 11, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday ↗

July 01, 2022

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase...

Via Benzinga

Aspen Aerogels And 28 Stocks Moving Premarket ↗

June 30, 2022

Gainers

Via Benzinga

Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session ↗

June 30, 2022

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical...

Via Benzinga

The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data ↗

June 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday ↗

June 30, 2022

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.